Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C6H10O4 |
| Molecular Weight | 146.1412 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12
InChI
InChIKey=KLDXJTOLSGUMSJ-JGWLITMVSA-N
InChI=1S/C6H10O4/c7-3-1-9-6-4(8)2-10-5(3)6/h3-8H,1-2H2/t3-,4+,5-,6-/m1/s1
| Molecular Formula | C6H10O4 |
| Molecular Weight | 146.1412 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Isosorbide is an effective hyperosmotic agent which can be administered orally without gastrointestinal irritation. It is absorbed quantitatively and more than 95% of the administered dose is excreted unchanged in the urine. Oral administration of a 50% solution to rabbits or man results in prompt increases in osmolarity of the serum and profound decreases in intraocular pressure. The drug proves useful in acute primary and secondary glaucomas, and as preoperative medication for various surgical procedures including cataract extraction, retinal detachment, corneal transplant, and glaucoma operations.
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | ISMOTIC Approved UseIsosorbide Mononitrate Extended-Release Tablets are indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. Launch Date1974 |
|||
| Palliative | ISMOTIC Approved UseIsosorbide Mononitrate Extended-Release Tablets are indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. Launch Date1974 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.16 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4695381/ |
100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ISOSORBIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4695381/ |
100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ISOSORBIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Physicochemical characterisation of a novel thermogelling formulation for percutaneous penetration of 5-aminolevulinic acid. | 2008-06 |
|
| Prevention of recurrent esophageal variceal hemorrhage: review and current recommendations. | 2007-12-06 |
|
| Occlusal management for a patient with aural symptoms of unknown etiology: a case report. | 2007-09-12 |
|
| Value of symptoms to predict tilt testing outcome in patients with clinical suspicion of vasovagal syncope. | 2007-07 |
|
| Inhibition of NAD(P)H oxidase reduces apoptosis and avascular retina in an animal model of retinopathy of prematurity. | 2007-06-12 |
|
| Potential and utilization of thermophiles and thermostable enzymes in biorefining. | 2007-03-15 |
|
| High performance liquid chromatography-electrospray ionization mass spectrometric determination of isosorbide 5-mononitrate in human plasma. | 2007-02-01 |
|
| [Milestones of cardiovascular therapy. III. Nitroglycerin]. | 2007 |
|
| Neuropsychiatric consequences of cardiovascular medications. | 2007 |
|
| Co- and terpolyesters based on isosorbide and succinic acid for coating applications: synthesis and characterization. | 2006-12 |
|
| Effects of simple and complex motion patterns on gene expression of chondrocytes seeded in 3D scaffolds. | 2006-11 |
|
| [Comparative study of propranolol versus propranolol plus isosorbide 5-mononitrate in portal hypertension in cirrhotics. Evaluating splanchnic hemodynamics with color Doppler ultrasound]. | 2006-10-27 |
|
| Organic solvents as vehicles for precipitating liquid embolics: a comparative angiotoxicity study with superselective injections of swine rete mirabile. | 2006-10 |
|
| Vestibular evoked myogenic potentials in acute acoustic trauma. | 2006-10 |
|
| [Prevention of variceal bleeding and measurement of hepatic vein pressure gradient]. | 2006-09 |
|
| Allergic and nonallergic reactions to nitroglycerin. | 2006-08-18 |
|
| Effectiveness of oral route isosorbide 5-mononitrate on peritoneal solute and fluid transports in CAPD patients. | 2006-08 |
|
| IMOP: randomised placebo controlled trial of outpatient cervical ripening with isosorbide mononitrate (IMN) prior to induction of labour - clinical trial with analyses of efficacy, cost effectiveness and acceptability. | 2006-07-25 |
|
| Endolymphatic hydrops as a cause of audio-vestibular manifestations in relapsing polychondritis. | 2006-05 |
|
| Aortic responsiveness to nitric oxide is affected by seasonal variation. | 2006-05 |
|
| Coronary artery spasm and the polymorphisms of the endothelial nitric oxide synthase gene. | 2006-04 |
|
| Composition analysis of two batches of polysorbate 60 using MS and NMR techniques. | 2006-03-18 |
|
| Quantification of isosorbide 5-mononitrate in human plasma by liquid chromatography-tandem mass spectrometry using atmospheric pressure photoionization. | 2006-03-07 |
|
| Cerebrovascular blood flow during the near syncopal phase of head-up tilt test: a comparative study in different types of neurally mediated syncope. | 2006-03 |
|
| Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. | 2006-03 |
|
| Endothelial dysfunction in patients with ulcerative colitis. | 2006-03 |
|
| Should drug therapy be personalized based on race? | 2006-03 |
|
| Cholesteric polymer guest-host mixture with circularly polarized fluorescence: two ways for phototuning of polarization and its intensity. | 2006-02-23 |
|
| BiDil: false promises: faulty statistics and reasoning have lead to the first "racial medicine". | 2006-02-08 |
|
| [Usefulness of sublingual isosorbide to assess the reversibility of pulmonary hypertension in cardiac transplant candidates]. | 2006-02 |
|
| Use of simultaneous pressure and velocity measurements to estimate arterial wave speed at a single site in humans. | 2006-02 |
|
| Low serum bilirubin levels are independently and inversely related to impaired flow-mediated vasodilation and increased carotid intima-media thickness in both men and women. | 2006-02 |
|
| Antidiuretic hormone and osmolality in isosorbide therapy and glycerol test. | 2006 |
|
| Synthesis and structure activity relationships (SAR) of a new class of potent and selective butyrylcholinesterase inhibitors. | 2005-12-15 |
|
| Novel isosorbide-based substrates for human butyrylcholinesterase. | 2005-12-15 |
|
| Isosorbide dinitrate and hydralazine hydrochloride: a review of efficacy and safety. | 2005-11 |
|
| Preservation of platelet responsiveness to nitroglycerine despite development of vascular nitrate tolerance. | 2005-10 |
|
| Effect of preventive and regressive isosorbide 5-mononitrate treatment on catecholamine levels in plasma, platelets, adrenals, left ventricle and aorta in cyclosporin A-induced hypertensive rats. | 2005-09-30 |
|
| Cooperative type of platelet hypersensitivity to ADP. | 2005-09 |
|
| Cerebral blood flow during supine rest and the first minute of head-up tilt in patients with orthostatic intolerance. | 2005-09 |
|
| BiDil raises questions about race as a marker. | 2005-08 |
|
| Short-term medical management of hydrocephalus. | 2005-08 |
|
| The impact of race on response to RAAS inhibition. | 2005-08 |
|
| Direct gas measurements indicate that the novel cyclooxygenase inhibitor AZD3582 is an effective nitric oxide donor in vivo. | 2005-07 |
|
| Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005-06 |
|
| [Nitric oxide and cardiologic drugs]. | 2005-05 |
|
| Hydrogen peroxide overload increases adriamycin-induced apoptosis of SaOS(2)FM, a manganese superoxide dismutase-overexpressing human osteosarcoma cell line. | 2005-05 |
|
| Manganese superoxide dismutase overexpression changes plating efficiency bidirectionally according to change in redox for SaOS2 human osteosarcoma cell line. | 2005-04 |
|
| The coming of age of multicultural medicine. | 2005-03 |
|
| Isosorbide delays gentamicin-induced vestibular sensory cell death. | 2005 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:52:20 GMT 2025
by
admin
on
Mon Mar 31 17:52:20 GMT 2025
|
| Record UNII |
WXR179L51S
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29707
Created by
admin on Mon Mar 31 17:52:20 GMT 2025 , Edited by admin on Mon Mar 31 17:52:20 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
211-492-3
Created by
admin on Mon Mar 31 17:52:20 GMT 2025 , Edited by admin on Mon Mar 31 17:52:20 GMT 2025
|
PRIMARY | |||
|
6057
Created by
admin on Mon Mar 31 17:52:20 GMT 2025 , Edited by admin on Mon Mar 31 17:52:20 GMT 2025
|
PRIMARY | RxNorm | ||
|
1352008
Created by
admin on Mon Mar 31 17:52:20 GMT 2025 , Edited by admin on Mon Mar 31 17:52:20 GMT 2025
|
PRIMARY | |||
|
CHEMBL1200660
Created by
admin on Mon Mar 31 17:52:20 GMT 2025 , Edited by admin on Mon Mar 31 17:52:20 GMT 2025
|
PRIMARY | |||
|
m6540
Created by
admin on Mon Mar 31 17:52:20 GMT 2025 , Edited by admin on Mon Mar 31 17:52:20 GMT 2025
|
PRIMARY | Merck Index | ||
|
ISOSORBIDE
Created by
admin on Mon Mar 31 17:52:20 GMT 2025 , Edited by admin on Mon Mar 31 17:52:20 GMT 2025
|
PRIMARY | |||
|
DTXSID5046196
Created by
admin on Mon Mar 31 17:52:20 GMT 2025 , Edited by admin on Mon Mar 31 17:52:20 GMT 2025
|
PRIMARY | |||
|
40725
Created by
admin on Mon Mar 31 17:52:20 GMT 2025 , Edited by admin on Mon Mar 31 17:52:20 GMT 2025
|
PRIMARY | |||
|
652-67-5
Created by
admin on Mon Mar 31 17:52:20 GMT 2025 , Edited by admin on Mon Mar 31 17:52:20 GMT 2025
|
PRIMARY | |||
|
3105
Created by
admin on Mon Mar 31 17:52:20 GMT 2025 , Edited by admin on Mon Mar 31 17:52:20 GMT 2025
|
PRIMARY | |||
|
D007547
Created by
admin on Mon Mar 31 17:52:20 GMT 2025 , Edited by admin on Mon Mar 31 17:52:20 GMT 2025
|
PRIMARY | |||
|
WXR179L51S
Created by
admin on Mon Mar 31 17:52:20 GMT 2025 , Edited by admin on Mon Mar 31 17:52:20 GMT 2025
|
PRIMARY | |||
|
100000082855
Created by
admin on Mon Mar 31 17:52:20 GMT 2025 , Edited by admin on Mon Mar 31 17:52:20 GMT 2025
|
PRIMARY | |||
|
12597
Created by
admin on Mon Mar 31 17:52:20 GMT 2025 , Edited by admin on Mon Mar 31 17:52:20 GMT 2025
|
PRIMARY | |||
|
1501
Created by
admin on Mon Mar 31 17:52:20 GMT 2025 , Edited by admin on Mon Mar 31 17:52:20 GMT 2025
|
PRIMARY | |||
|
SUB08334MIG
Created by
admin on Mon Mar 31 17:52:20 GMT 2025 , Edited by admin on Mon Mar 31 17:52:20 GMT 2025
|
PRIMARY | |||
|
6433
Created by
admin on Mon Mar 31 17:52:20 GMT 2025 , Edited by admin on Mon Mar 31 17:52:20 GMT 2025
|
PRIMARY | |||
|
C60773
Created by
admin on Mon Mar 31 17:52:20 GMT 2025 , Edited by admin on Mon Mar 31 17:52:20 GMT 2025
|
PRIMARY | |||
|
DB09401
Created by
admin on Mon Mar 31 17:52:20 GMT 2025 , Edited by admin on Mon Mar 31 17:52:20 GMT 2025
|
PRIMARY | |||
|
WXR179L51S
Created by
admin on Mon Mar 31 17:52:20 GMT 2025 , Edited by admin on Mon Mar 31 17:52:20 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
